Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after undergoing surgery to remove the tumor. This test may also determine whether immunotherapy treatment administered after surgery has been effective or if residual bladder cancer remains.
The ability to predict treatment response is critical in oncology, as it allows for timely adjustments in therapy, potentially improving outcomes and reducing unnecessary side effects. Bladder cancer is one of the most common cancers worldwide, and its management often involves surgical resection followed by adjuvant therapies such as immunotherapy. However, monitoring for residual disease has traditionally relied on invasive procedures like cystoscopy or imaging, which can be costly and uncomfortable.
This new non-invasive approach analyzes urine samples for circulating tumor DNA (ctDNA), which is shed by cancer cells into the urine. By detecting the presence and quantity of ctDNA, the test can identify patients who may have residual disease after surgery. Moreover, changes in ctDNA levels over time could reflect how well a patient is responding to immunotherapy, offering a real-time biomarker for treatment efficacy.
The development of such liquid biopsy tests is a growing field in precision oncology. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are actively working on next-generation immunotherapies for various cancers, including bladder cancer. The ability to monitor treatment response non-invasively could accelerate the clinical development of these therapies and improve patient management.
The implications of this research are significant. For patients, a simple urine test could replace repeated invasive procedures, reducing anxiety and healthcare costs. For clinicians, it provides a tool to make more informed decisions about continuing, switching, or stopping therapies. Early detection of residual disease could prompt additional treatment before cancer progresses, potentially improving survival rates.
However, the test must undergo rigorous validation in larger clinical trials before it can be adopted widely. Researchers are optimistic that this approach could be extended to other urological cancers and even beyond, as ctDNA is present in various bodily fluids. The study highlights the potential of liquid biopsies to transform cancer care by enabling personalized, real-time monitoring.
For more information on the latest developments in biotechnology and life sciences, visit BioMedWire at https://www.BioMedWire.com.
